RecruitingNCT05978141
A Registry for People With T-cell Lymphoma
The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
1,000 participants
Start Date
Jul 27, 2023
Study Type
OBSERVATIONAL
Conditions
T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic LeukemiaT-cell Large Granular Lymphocytic LeukemiaChronic Lymphoproliferative Disorder of NK CellsAggressive NK-cell LeukemiaSystemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedMycosis FungoidesAdult T-cell Leukemia/LymphomaHepatosplenic T-cell LymphomaSubcutaneous Panniculitis-Like T-Cell LymphomaIndolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal TractPrimary Cutaneous Acral CD8-Positive T-Cell LymphomaAngioimmunoblastic T-cell LymphomaFollicular T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeAnaplastic Large Cell Lymphoma, ALK-PositiveSezary SyndromeHydroa Vacciniforme-Like Lymphoproliferative DisorderExtranodal NK/T Cell Lymphoma, Nasal TypeEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaChronic Active EBV Infection of T-and NK-Cell Type, Systemic FormIntestinal T-Cell Lymphoma, Not Otherwise SpecifiedPrimary Cutaneous Anaplastic Large Cell LymphomaPrimary Cutaneous T-cell LymphomaPrimary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell LymphomaAnaplastic Large Cell Lymphoma, ALK-negativeBreast Implant-Associated Anaplastic Large Cell Lymphoma
Summary
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Eligibility
Inclusion Criteria32
- Written informed consent
- Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
- Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
- T-cell prolymphocytic leukemia
- T-cell large granular lymphocytic leukemia
- Chronic lymphoproliferative disorder of NK cells
- Aggressive NK-cell leukemia
- Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
- Chronic active EBV infection of T- and NK-cell type, systemic form
- Hydroa vacciniforme-like lymphoproliferative disorder
- Adult T-cell leukemia/lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Enteropathy-associated T-cell lymphoma
- Monomorphic epitheliotropic intestinal T-cell lymphoma
- Intestinal T-cell lymphoma, not otherwise specified (NOS)
- Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
- Sézary syndrome
- Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
- Primary cutaneous Gamma-Delta T-cell lymphoma
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
- Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
- Peripheral T-cell lymphoma, not otherwise specified
- Angioimmunoblastic T-cell lymphoma
- Follicular T-cell lymphoma
- Nodal peripheral T-cell lymphoma with TFH phenotype
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Breast-implant associated anaplastic large cell lymphoma.
- NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.
Exclusion Criteria2
- Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
- Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.
Interventions
OTHEROptional Blood Sample and Nail Sample
Participants may provide optional research blood and nail samples for biobanking and future use
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05978141
Related Trials
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT0656104817 locations
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
NCT065084632 locations
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT0547592537 locations
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT063903193 locations
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
NCT070554771 location